Literature DB >> 23406386

Prevalence of lymphedema in women undergoing treatment for breast cancer in a referral center in southeastern Brazil.

Daniella M F Paiva1, Vivian O Rodrigues, Marcelle G Cesca, Pamella V Palma, Isabel C G Leite.   

Abstract

BACKGROUND: Lymphedema is a highly prevalent condition in women who have undergone treatment for breast cancer. Lymphedema negatively affects the quality of life. The objective of this study was to estimate the prevalence of lymphedema and associated factors in women treated for breast cancer in the municipality of Juiz de Fora.
METHODS: We performed a cross-sectional study that evaluated 250 women who were being treated for breast cancer. Pre-screening of the sample by analysis of medical records was performed to select women who met the inclusion criteria as follows: women who had an operation more than 6 months ago; absence of active disease, locoregional or distant; the absence of functional change in the affected limb before surgery, which could lead to swelling of the limb; and simulating or masking symptoms of lymphedema, such as bursitis, tendonitis, and work-related musculoskeletal disorders. Women with bilateral breast cancer, absence of axillary intervention (partial or complete axillary dissection and/or SLN biopsy), active disease in the region, or lympho-venous alteration of the limb before surgery were excluded. Data were collected from the medical records of the selected cases, and they subsequently underwent an interview and a physical assessment.
RESULTS: The prevalence of lymphedema was 44.8%. There were medical records on the presence of this condition in 5.4% of cases. With regard to shoulder joint mobility, restrictions on abduction movements, internal and external rotation, and anterior shoulder adduction were significantly associated with lymphedema. Variables, including the presence of seroma, vascular changes, time elapsed after surgery, episodes of redness in the extremities, and cuticle removal from the hand with pliers were considered as major associated factors for lymphedema (p<0.05).
CONCLUSIONS: The prevalence of 44.8% for lymphedema found in this study is considered to be relevant because it is a morbidity that produces psychological, physical, and functional damage in patients with this condition. The planning of health programs and services appropriate for the immediate postoperative treatment of women with breast cancer, and increasing the awareness of health professionals regarding the early diagnosis of lymphedema, can help minimize the morbidity of this disease.

Entities:  

Mesh:

Year:  2013        PMID: 23406386      PMCID: PMC3577444          DOI: 10.1186/1472-6874-13-6

Source DB:  PubMed          Journal:  BMC Womens Health        ISSN: 1472-6874            Impact factor:   2.809


  31 in total

1.  Motion restriction and axillary web syndrome after sentinel node biopsy and axillary clearance in breast cancer.

Authors:  Marjut Leidenius; Esa Leppänen; Leena Krogerus; Karl von Smitten
Journal:  Am J Surg       Date:  2003-02       Impact factor: 2.565

2.  Axillary web syndrome after axillary dissection.

Authors:  A H Moskovitz; B O Anderson; R S Yeung; D R Byrd; T J Lawton; R E Moe
Journal:  Am J Surg       Date:  2001-05       Impact factor: 2.565

3.  Lymphedema and quality of life in survivors of early-stage breast cancer.

Authors:  Sarah M Beaulac; Lindsay A McNair; Thayer E Scott; Wayne W LaMorte; Maureen T Kavanah
Journal:  Arch Surg       Date:  2002-11

4.  Estimating the probability of lymphedema after breast cancer surgery.

Authors:  Atilla Soran; Wen-Chi Wu; Abuzer Dirican; Ronald Johnson; Oya Andacoglu; John Wilson
Journal:  Am J Clin Oncol       Date:  2011-10       Impact factor: 2.339

5.  Treatment of morbidity associated with the management of the axilla in breast-conserving therapy.

Authors:  J Johansen; J Overgaard; M Blichert-Toft; M Overgaard
Journal:  Acta Oncol       Date:  2000       Impact factor: 4.089

6.  Lymphedema of the arm and breast in irradiated breast cancer patients: risks in an era of dramatically changing axillary surgery.

Authors:  Thomas E Goffman; Christine Laronga; Lori Wilson; David Elkins
Journal:  Breast J       Date:  2004 Sep-Oct       Impact factor: 2.431

7.  Prevalence and risk factors for development of lymphedema following breast cancer treatment.

Authors:  S V S Deo; S Ray; G K Rath; N K Shukla; M Kar; S Asthana; V Raina
Journal:  Indian J Cancer       Date:  2004 Jan-Mar       Impact factor: 1.224

8.  Axilla surgery severely affects quality of life: results of a 5-year prospective study in breast cancer patients.

Authors:  Jutta Engel; Jacqueline Kerr; Anne Schlesinger-Raab; Hansjörg Sauer; Dieter Hölzel
Journal:  Breast Cancer Res Treat       Date:  2003-05       Impact factor: 4.872

9.  Benefits of supervised group exercise programme for women being treated for early stage breast cancer: pragmatic randomised controlled trial.

Authors:  Nanette Mutrie; Anna M Campbell; Fiona Whyte; Alex McConnachie; Carol Emslie; Laura Lee; Nora Kearney; Andrew Walker; Diana Ritchie
Journal:  BMJ       Date:  2007-02-16

10.  The efficacy of physiotherapy upon shoulder function following axillary dissection in breast cancer, a randomized controlled study.

Authors:  Carien H G Beurskens; Caro J T van Uden; Luc J A Strobbe; Rob A B Oostendorp; Theo Wobbes
Journal:  BMC Cancer       Date:  2007-08-30       Impact factor: 4.430

View more
  9 in total

1.  Factors influencing response to lymphedema treatment in patients with breast cancer-related lymphedema.

Authors:  Sibel Eyigör; Ece Cinar; Ismail Caramat; Burcu Koc Unlu
Journal:  Support Care Cancer       Date:  2015-02-08       Impact factor: 3.603

2.  Atypical presentation of axillary web syndrome (AWS) in a male squash player: a case report.

Authors:  Patrick Welsh; David Gryfe
Journal:  J Can Chiropr Assoc       Date:  2016-12

Review 3.  A systematic review of axillary web syndrome (AWS).

Authors:  W M Yeung; S M McPhail; S S Kuys
Journal:  J Cancer Surviv       Date:  2015-02-15       Impact factor: 4.442

4.  Axillary web syndrome is not a risk factor for lymphoedema after 10 years of follow-up.

Authors:  Bárbara Reis Wariss; Rejane Medeiros Costa; Ana Carolina Padula Ribeiro Pereira; Rosalina Jorge Koifman; Anke Bergmann
Journal:  Support Care Cancer       Date:  2016-10-04       Impact factor: 3.603

5.  Assessment of Risk Factors in Patients who presented to the Outpatient Clinic for Breast Cancer-Related Lymphedema.

Authors:  Aslı Gençay Can; Emel Ekşioğlu; Zeynep Tuba Bahtiyarca; Fatma Aytül Çakcı
Journal:  J Breast Health       Date:  2016-01-01

6.  Combined decongestive therapy and reduction of pain and heaviness in patients with breast cancer-related lymphedema.

Authors:  Zahra Sheikhi Mobarakeh; Parisa Mokhtari-Hesari; Masomeh Lotfi-Tokaldany; Ali Montazeri; Mahnaz Heidari; Fatemeh Zekri
Journal:  Support Care Cancer       Date:  2019-02-07       Impact factor: 3.603

7.  The Attitudes of Brazilian Breast Surgeons on Axillary Management in Early Breast Cancer-10 Years after the ACOSOG Z0011 Trial First Publication.

Authors:  Eduardo Camargo Millen; Francisco Pimentel Cavalcante; Felipe Zerwes; Guilherme Novita; Alessandra Borba Anton de Souza; João Henrique Penna Reis; Helio Rubens de Oliveira Filho; Luciana Naíra de B L Limongi; Barbara Pace Silva de Assis Carvalho; Adriana Magalhães de Oliveira Freitas; Monica Travassos Jourdan; Vilmar Marques de Oliveira; Ruffo Freitas-Junior
Journal:  Ann Surg Oncol       Date:  2021-09-27       Impact factor: 5.344

8.  Prevalence and incidence of cancer related lymphedema in low and middle-income countries: a systematic review and meta-analysis.

Authors:  Eric Torgbenu; Tim Luckett; Mark A Buhagiar; Sungwon Chang; Jane L Phillips
Journal:  BMC Cancer       Date:  2020-06-29       Impact factor: 4.430

9.  The Level of Lymphedema Awareness among Women with Breast Cancer in the Kingdom of Saudi Arabia.

Authors:  Fatmah Alsharif; Wedad Almutairi; Faygah Shibily; Fatmah Alhothari; Fidaa Batwa; Nidaa Batwa; Lujain Alharbi
Journal:  Int J Environ Res Public Health       Date:  2021-01-13       Impact factor: 3.390

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.